Gliadel Wafer (carmustine implant)

News alerts, weekly reports and conference planners

Company:

Azurity Pharma, Eisai

Drug class:

Alkylating agent

Related drugs:

‹

›

22d

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM (clinicaltrials.gov)

P1/2, N=8, Terminated, St. Joseph's Hospital and Medical Center, Phoenix | N=80 --> 8 | Unknown status --> Terminated; met stopping rules for futility

22 days ago

Enrollment change • Trial termination

temozolomide • Gliadel Wafer (carmustine implant)

6ms

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry (clinicaltrials.gov)

P=N/A, N=272, Active, not recruiting, Arbor Pharmaceuticals, Inc. | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

6 months ago

Trial completion date • Trial primary completion date

Gliadel Wafer (carmustine implant)

2years

Interstitial Control-Released Polymer Carrying a Targeting Small-Molecule Drug Reduces PD-L1 and MGMT Expression in Recurrent High-Grade Gliomas with TMZ Resistance. (PubMed, Cancers (Basel))

Furthermore, temozolomide (TMZ) resistance caused by O-methylguanine-DNA-methyltransferase (MGMT) activation and programmed cell death-ligand 1 (PD-L1) expression leads to immune-cold lesions that result in poorer prognosis...Furthermore, BP inhibited PD-L1 expression, thereby activating T-cell cytotoxicity and increasing interferon-gamma (IFN-γ) secretion. The better therapeutic effect of Cerebraca wafer on recurrent high-grade glioma could occur through re-sensitization of TMZ and reduction of PD-L1.

2 years ago

Journal • PD(L)-1 Biomarker • IO biomarker

MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma)

PD-L1 expression

temozolomide • Gliadel Wafer (carmustine implant)